title: [Treatment of severe infection in patients with hematological disorders by cefminox. Tokai Infection Study Group].
abstract: Sixty-three infectious episodes in 61 patients with hematological disorders were treated with cefminox (CMNX, MT-141), a new antibiotics in the cephamycin group. CMNX was given by 1 hour infusion every 8 to 12 hours in a dose of 4 to approximately 6 g per day for 3 to 12 days, not being combined with other antibiotics. CMNX was effective in 45% of total cases. In 24 cases, the number of granulocytes at the start of CMNX were less than 500/mm3, and 11 cases (46%) of them responded to CMNX. Thus, CMNX was found effective in severe infections in patients with hematological disorders. No serious side effects attributable to CMNX were noted.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002513:Cephamycins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged
chemical_list: D002513:Cephamycins; C046079:cefminox